利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

509 条记录 (耗时 0.029 秒)

    Therapeutic compositions and methods relating to prolactin releasing peptide (PrRP)
    54.
    发明申请
    Therapeutic compositions and methods relating to prolactin releasing peptide (PrRP) 审中-公开
    与催乳素释放肽（PrRP）相关的治疗组合物和方法

    公开(公告)号：US20030171270A1

    公开(公告)日：2003-09-11

    申请号：US10096777

    申请日：2002-03-12

    申请人： Regents of the University of California

    发明人： Olivier Civelli ,  Steven Lin

    IPC分类号： A61K038/22 ,  A61K031/496 ,  A61K031/19

    CPC分类号： G01N33/74 ,  A61K31/00

    摘要： The invention provides a substantially pure Prolactin Releasing Peptide (PrRP) functional analog which suppresses absence seizures in a mammal, and related pharmaceutical compositions. The invention also provides a method of controlling absence seizures in a mammal, by administering to a mammal susceptible to absence seizures an effective amount of PrRP or a PrRP functional analog. Also provided are methods of identifying a compound that modulates AMPA receptor signaling in a mammal, by providing a compound that is a PrRP or PrRP functional analog, and determining the ability of the compound to modulate AMPA receptor signaling. The invention also provides methods of identifying a compound for controlling absence seizures in a mammal, by providing a compound that is a PrRP or PrRP functional analog, and determining the ability of the compound to control absence seizures in a mammal. Also provided are pharmaceutical compositions for controlling absence seizures in a mamma. The compositions and related methods contain a compound identified by the methods of the invention as a compound that modulates AMPA receptor signaling or as a compound that controls absence seizures.

    摘要翻译： 本发明提供了基本上纯的催乳素释放肽（PrRP）功能类似物，其抑制哺乳动物的不存在发作，以及相关的药物组合物。 本发明还提供了一种控制哺乳动物不存在癫痫发作的方法，该方法通过给予感染不发作的哺乳动物有效量的PrRP或PrRP功能性类似物。 还提供了通过提供作为PrRP或PrRP功能类似物的化合物以及测定化合物调节AMPA受体信号传导的能力来鉴定调节哺乳动物AMPA受体信号传导的化合物的方法。 本发明还提供了通过提供PrRP或PrRP功能类似物的化合物以及确定化合物控制哺乳动物中不存在癫痫发作的能力来鉴定用于控制哺乳动物不存在癫痫发作的化合物的方法。 还提供了用于控制乳房中不存在癫痫发作的药物组合物。 组合物和相关方法含有通过本发明的方法鉴定的化合物，其作为调节AMPA受体信号传导的化合物或作为控制不发作的化合物。

    Carboxyfullerenes and methods of use thereof
    55.
    发明申请
    Carboxyfullerenes and methods of use thereof 审中-公开
    羧基富勒烯及其使用方法

    公开(公告)号：US20030162837A1

    公开(公告)日：2003-08-28

    申请号：US10083283

    申请日：2002-02-23

    发明人： Laura L. Dugan ,  Eva G. Lovett ,  Kevin L. Quick ,  Joshua I. Hardt

    IPC分类号： A61K031/19

    CPC分类号： B82Y30/00 ,  A61K31/19 ,  B82Y40/00 ,  C01B32/15 ,  C01B32/152 ,  C07C61/39 ,  C07C2604/00

    摘要： The instant invention is a method for increasing a metazoan's lifespan, comprising administering a carboxylated derivative of a C60 fullerene. The instant invention further is a process for extending a metazoan's lifespan by administering a superoxide dismutase-mimetic as well as a composition comprising a superoxide dismutase-mimetic. Further, the instant invention comprises a pharmaceutical composition comprising carboxyfullerenes having x pairs of adjacent carbon atoms bonded to two carbons of the C60 sphere wherein said adjacent carbon atom is further bonded to two groups of the general formula nullCOOH and nullR, wherein R is independently selected from the group consisting of nullCOOH and nullH, and wherein x is at least 1. A further embodiment is a non-metal containing composition which can catalytically eliminate two biologically reactive species. Another embodiment is a method of enhancing elimination of reactive oxygen species in eukaryotic cells by contacting cells with a superoxide dismutase mimetic.

    摘要翻译： 本发明是一种增加后生动物寿命的方法，包括施用C 60富勒烯的羧化衍生物。 本发明还是通过施用超氧化物歧化酶模拟物以及包含超氧化物歧化酶 - 模拟物的组合物来延长后生动物的寿命的方法。 此外，本发明包括药物组合物，其包含具有与所述C 60球的两个碳键合的x对相邻碳原子的羧基富勒烯，其中所述相邻碳原子进一步键合到两个通式-COOH和-R的两个基团，其中R为 独立地选自-COOH和-H，并且其中x至少为1.另一个实施方案是可以催化消除两种生物活性物质的非含金属组合物。 另一个实施方案是通过使细胞与超氧化物歧化酶模拟物接触来增强真核细胞中活性氧的消除的方法。

    SUBSTANCE TO PREVENT OR REVERSE WEIGHT GAIN INDUCED BY PSYCHOACTIVE AGENTS
    59.
    发明申请
    SUBSTANCE TO PREVENT OR REVERSE WEIGHT GAIN INDUCED BY PSYCHOACTIVE AGENTS 无效
    物质预防或反复由精神病药物引起的体重增加

    公开(公告)号：US20030096808A1

    公开(公告)日：2003-05-22

    申请号：US09280279

    申请日：1999-03-29

    发明人： JON M. MILLER

    IPC分类号： A61K031/551 ,  A61K031/5513 ,  A61K031/519 ,  A61K031/495 ,  A61K031/4439 ,  A61K031/19

    CPC分类号： A61K31/5513 ,  A61K31/00 ,  A61K31/19 ,  A61K31/4439 ,  A61K31/495 ,  A61K31/519 ,  A61K31/551

    摘要： A substance to prevent or reverse weight gain induced by psychoactive agents (10) having an antipsychotic drug (12) or mood stabilizing drug (14) in a concentration from 0.01% to 99.99% in combination with a histamine H2-receptor antagonist (16) in a concentration from 99.99% to 0.01%. The antipsychotic drug (12) is selected from a group consisting of olanzapine (12A), clozapine (12B), risperidone (12C), and quetiapine (12D). The antipsychotic drug (12) is typically in a concentration of 10% to 90%, 30% to 60% and 50%. The mood stabilizing drug (14) is selected from a group consisting of divalproex sodium (14A), valproic acid (14B), and mirtazapine (14C). The mood stabilizing drug (14) is typically in a concentration of 10% to 90%, 30% to 60% and 50%. The histamine H2-receptor antagonist (16) is selected from a group consisting of nizatidine (16A), famotidine (16B), cimetidine (16C) and ranitidine (16D). The histamine H2-receptor antagonist (16) is in a concentration of 90% to 10%. The histamine H2-receptor antagonist (16) is typically in a concentration of 60% to 30% and 50%.

    摘要翻译： 与组胺H2受体拮抗剂（16）组合，具有0.01％至99.99％浓度的具有抗精神病药物（12）或情绪稳定药物（14）的精神活性剂（10）引起的物质， 浓度为99.99％至0.01％。 抗精神病药（12）选自奥氮平（12A），氯氮平（12B），利培酮（12C）和喹硫平（12D）。 抗精神病药（12）的浓度通常为10％至90％，30％至60％和50％。 情绪稳定药物（14）选自二丙酸钠（14A），丙戊酸（14B）和米氮平（14C）组成的组。 情绪稳定药物（14）通常为10％至90％，30％至60％和50％的浓度。 组胺H2受体拮抗剂（16）选自尼扎给丁（16A），法莫替丁（16B），西咪替丁（16C）和雷尼替丁（16D）。 组胺H2受体拮抗剂（16）的浓度为90％至10％。 组胺H2受体拮抗剂（16）通常浓度为60％至30％和50％。

    Galenical preparations of dapsone and related sulphones, and method of therapeutic and preventative treatment of disease
    60.
    发明申请
    Galenical preparations of dapsone and related sulphones, and method of therapeutic and preventative treatment of disease 审中-公开
    氨苯砜及相关砜的制备方法，以及治疗和预防性治疗疾病的方法

    公开(公告)号：US20030092635A1

    公开(公告)日：2003-05-15

    申请号：US10149108

    申请日：2002-08-26

    发明人： A K Gunnar Aberg ,  Alexander Zolotoy ,  Allen I Bain

    IPC分类号： A61K031/70 ,  A61K031/19 ,  A61K031/135 ,  A61K031/16

    CPC分类号： A61K31/145 ,  A61K9/2013 ,  A61K9/2018 ,  A61K9/205 ,  A61K9/2059 ,  A61K9/2866 ,  A61K31/136 ,  A61K31/16 ,  A61K31/167 ,  A61K31/426 ,  A61K31/7024 ,  Y02A50/411

    摘要： Dapsone and related sulfones are known to have therapeutic activity against leprosy, dermatitis herpetiformis, actinomycotic mycetoma, asthma, malaria, rheumatoid arthritis, Kaposinulls sarcoma, pneumocystis carininull (pneumonia), subcorneal pustular dermatosis and cystic acne, in patients in need of such therapy. These sulfones are also known to have therapeutic activity against memory loss in patients in need of such therapy, including patients suffering from Alzheimer's disease and related neurodegenerative disorders. It has now been found that new, modified-release formulations of dapsone and related sulfones may also be used that decrease side effects and increase effectiveness of the drugs. New methods are disclosed utilizing certain formulations of dapsone and related sulfones that improve the therapeutic index of said drugs. Side effects of these drugs are known to those skilled in the art and include, but are not restricted to anorexia, psychosis, agranulocytosis, peripheral neuritis, hemolysis, methemoglobinemia, nausea, vomiting, headache, dizziness, tachycardia, nervousness, insomnia and skin disorders. Modified-release (as defined herein) formulations of dapsone have now been found to avoid some or all of these side effects, and to have more efficacy on potency.

    摘要翻译： 已知氨苯砜和相关砜在需要这种治疗的患者中具有抗麻风病，疱疹样皮炎，放线菌素，哮喘，疟疾，类风湿关节炎，卡波西肉瘤，肺囊虫（肺炎），子宫内膜脓疱性皮肤病和囊性痤疮的治疗活性。 也已知这些砜具有对需要这种治疗的患者的记忆丧失的治疗活性，包括患有阿尔茨海默病和相关神经变性疾病的患者。 现在已经发现，也可以使用降低副作用并增加药物有效性的氨苯砜和相关砜的新的改良释放制剂。 公开利用改善所述药物的治疗指数的氨苯砜和相关砜的某些制剂的新方法。 这些药物的副作用是本领域技术人员已知的，包括但不限于厌食症，精神病，粒细胞缺乏症，周围神经炎，溶血，高铁血红蛋白血症，恶心，呕吐，头痛，头晕，心动过速，紧张，失眠和皮肤病 。 目前已经发现氨苯砜酮的改良释放（如本文定义）制剂避免了这些副作用中的一些或全部，并且对效力具有更多的功效。